Nuplazid pimavanserin regulatory update

FDA’s Psychopharmacologic Drugs Advisory Committee will meet on March 29 to discuss an NDA for Nuplazid pimavanserin from Acadia to treat Parkinson’s disease psychosis. The NDA is under Priority Revie...